Elekta Unity demonstrates promising quality of life outcomes for pancreas and prostate cancers at ASTRO Annual Meeting
SAN ANTONIO – Elekta (EKTA-B.ST) today announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy.
Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia.
In the study of pancreas tumors*, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67 percent of patients were alive one year after the end of treatment.
According to Dr. Marijn Intven, senior investigator on the study and radiation oncologist at University Medical Center Utrecht in the Netherlands: “These outcomes compare favorably to the historically dismal outcomes of pancreatic cancer. We, of course, are not satisfied until all patients are cured but we think we are on the right track.”
In the study of prostate cancers**, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation.
“As far as we know, this is the largest quality-of-life study of men with prostate cancer treated on an MR-Linac. The results so far are consistent with physician-reported outcomes and suggest that this treatment strategy is well tolerated, especially in men who are treated with on-line adaptation,” said Dr. William Hall, senior investigator and radiation oncologist at the Froedtert & the Medical College of Wisconsin Clinical Cancer Center in the United States.
Gustaf Salford, CEO of Elekta, said: “These results from pancreas and prostate cohorts in the MOMENTUM Study are deeply gratifying. We hope that patients and their families who are struggling with a new diagnosis of pancreas or prostate cancer take some hope from these studies. Even with intensive curative treatments, quality of life can be maintained.”
To learn more about Elekta Unity, visit https://www.elekta.com/products/radiation-therapy/unity/.
*2428 Clinical Outcomes after MRI Guided Stereotactic Body Radiotherapy for (Peri-) Pancreatic Tumors
H. Eijkelenkamp et al.
**3014 EQ5D-5L Scores in Men Undergoing Radiation Therapy for Prostate Cancer Using a 1.5 MR linac Included in the MOMENTUM (NCT04075305) Prospective Multi Institutional Trial
A.M. Schottstaedt1 et al.
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.